Canadian insomnia guidelines — what CADTH, Health Canada, and Canadian clinicians actually recommend

What Canadian guidelines say about insomnia

Insomnia is the most common sleep disorder in Canada, affecting an estimated 13% of Canadians with chronic symptoms (3+ nights per week for 3+ months) and a far larger proportion experiencing occasional or short-term insomnia. Canadian clinical bodies — including the Canadian Sleep Society (CSS), the College of Family Physicians of Canada (CFPC), and CADTH — have each published guidance or evidence reviews that inform how Canadian clinicians should treat it.

The consistent message across all major Canadian guidelines is that Cognitive Behavioural Therapy for Insomnia (CBT-I) is the recommended first-line treatment for chronic insomnia. Pharmacotherapy is positioned as a short-term adjunct or second-line option, not a primary treatment. This aligns with international guidelines from the American Academy of Sleep Medicine and European Sleep Research Society but applies specifically within Canada's healthcare and regulatory context.

CADTH recommendations — CBT-I before medication

CADTH (the Canadian Drug and Technologies in Health agency — now part of the broader Canadian health technology assessment framework) has published systematic reviews and rapid evidence reports on insomnia treatment. Key findings from CADTH insomnia reviews:

• CBT-I produces durable outcomes: CADTH evidence reviews note that CBT-I benefits persist at 12- and 24-month follow-up, unlike pharmacotherapy whose effects are tied to continued use.
• Pharmacotherapy is appropriate short-term: For acute insomnia (less than 4 weeks), short-term use of sleep medication may be appropriate as a bridge while CBT-I is initiated or accessed.
• Z-drugs carry dependency risk: CADTH reviews highlight the dependency, tolerance, and rebound insomnia risks of z-drugs (zopiclone, zolpidem) and benzodiazepines, supporting guideline recommendations to limit their duration.
• Digital CBT-I is effective: CADTH has reviewed digital health technologies and found app-based and internet-delivered CBT-I programs clinically comparable to therapist-delivered treatment, improving access in underserved regions of Canada.

Health Canada approved treatments for insomnia

Health Canada regulates insomnia treatments across two streams: Natural Health Products (NHPs) and prescription or over-the-counter drugs.

Natural Health Products (NHPs)

Melatonin is the most significant NHP for insomnia in Canada. Unlike the US (where it is an unregulated supplement), Canadian melatonin products must carry an NPN (Natural Product Number) issued by Health Canada after pre-market review of safety, efficacy, and quality. Health Canada-approved melatonin indications include: sleep-onset insomnia, jet lag, and shift work sleep disorder. The approved dose range is 0.5–5 mg, with Health Canada guidance noting that lower doses (0.5–1 mg) are as effective as higher doses for most adults. Other NHP sleep aids — valerian, L-theanine, magnesium glycinate — may be sold with NPNs but with more limited efficacy claims.

Prescription sleep medications

Zopiclone (a z-drug) is the most commonly prescribed sleep medication in Canada and is only available by prescription. Benzodiazepines (temazepam, triazolam) are also prescribed but carry higher dependency risk. Health Canada has issued warnings on z-drugs regarding next-day impairment, particularly for driving, and recommends limiting use to the shortest effective duration.

OTC sleep aids

Diphenhydramine-based OTC sleep aids (Benadryl, ZzzQuil) are approved by Health Canada for occasional sleeplessness. Health Canada does not recommend these for chronic insomnia — tolerance develops within days, and antihistamine effects impair cognitive function the following day. They are not part of evidence-based insomnia treatment guidelines.

Canadian clinical practice guidelines

Several Canadian professional bodies have published or endorsed insomnia treatment guidelines:

• Canadian Sleep Society (CSS): The CSS endorses CBT-I as first-line treatment and has advocated for better access to trained CBT-I providers across Canada. The CSS also recognises that the therapist shortage requires digital CBT-I as a practical alternative.
• College of Family Physicians of Canada (CFPC): The CFPC's Choosing Wisely Canada campaign specifically recommends against prescribing sleep medication as first-line treatment for insomnia, and against routinely renewing sleep medication prescriptions without reassessment and discussion of CBT-I.
• Canadian Psychiatric Association (CPA): CPA guidelines for insomnia comorbid with anxiety and depression recommend addressing the insomnia directly with CBT-I rather than assuming it will resolve when the mental health condition is treated.
• Choosing Wisely Canada: This national initiative — endorsed by 40+ Canadian medical societies — includes specific recommendations against using benzodiazepines or z-drugs for insomnia in older adults, citing fall risk, cognitive impairment, and dependency.

Finding insomnia treatment in Canada

The largest practical barrier for Canadians is accessing CBT-I despite guidelines recommending it. Here are the routes available:

• Ask your GP for a sleep clinic referral — sleep medicine clinics at major Canadian hospitals offer CBT-I; wait times vary by province
• Extended health benefits — if your employer plan covers registered psychologists, CBT-I delivered by a psychologist trained in sleep qualifies
• Digital CBT-I programs — Sleepio, Somryst (Health Canada cleared), and the free Insomnia Coach app deliver evidence-based CBT-I without waitlists
• Provincial mental health programs — several provinces offer subsidised psychological therapy that can include CBT-I

For a full breakdown including city-by-city options, see our CBT-I treatment guide for Canadians →

Frequently asked questions